Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

Autor: Andrea M. Burden, Martijn C. G. J. Brouwers, Olaf H. Klungel, Frank de Vries, Judith van Dalem, Coen D.A. Stehouwer, Johanna H M Driessen
Přispěvatelé: RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: DA KFT Medische Staf (9), Clinical Pharmacy, RS: NUTRIM - R3 - Respiratory & Age-related Health, Epidemiologie, MUMC+: Centrum voor Chronische Zieken (3), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: HVC Pieken Maastricht Studie (9), Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), MUMC+: MA Endocrinologie (9), Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Oncology
EXENATIDE
POPULATION-BASED COHORT
STEATOHEPATITIS
Non-alcoholic Fatty Liver Disease
Risk Factors
Nonalcoholic fatty liver disease
MAGNETIC-RESONANCE
Thiazolidinedione
Aged
80 and over
education.field_of_study
Incidence
Liver Neoplasms
Hazard ratio
ASSOCIATION
Middle Aged
INSULIN
Treatment Outcome
Editorial
PIOGLITAZONE
Female
medicine.drug
Cohort study
Adult
Agonist
medicine.medical_specialty
Carcinoma
Hepatocellular
Adolescent
medicine.drug_class
Population
Glucagon-Like Peptide-1 Receptor
CLINICAL-TRIAL
Young Adult
Internal medicine
medicine
Humans
Hypoglycemic Agents
education
METAANALYSIS
Aged
Primary Health Care
Hepatology
business.industry
Liraglutide
medicine.disease
Sulfonylurea Compounds
Diabetes Mellitus
Type 2
LIRAGLUTIDE
Thiazolidinediones
business
Pioglitazone
Follow-Up Studies
Zdroj: Hepatology, 74(5), 2467-2477. Wiley
Hepatology, 74(5), 2467. John Wiley and Sons Ltd
Hepatobiliary Surg Nutr
Hepatology, 74 (5)
ISSN: 0270-9139
1527-3350
Popis: Background and Aims Thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) receptor agonists are potential pharmacological treatment options for patients at risk of NAFLD. Therefore, we examined the association between the risk of NAFLD and the use of TZDs and GLP-1 receptor agonists compared with the use of sulfonylureas (SUs) and insulins. Additionally, we calculated the incidence of HCC in users of TZDs and GLP-1 receptor agonists. Approach and Results We conducted a population-based cohort study using primary care data from the Clinical Practice Research Datalink database (2007-2018). All patients aged ≥18 with a prescription of an oral glucose-lowering agent or GLP-1 receptor agonist were included. The first prescription defined the start of follow-up. The primary outcome was a new diagnosis of NAFLD. Cox proportional hazards regression was used to estimate HRs and 95% CIs of the primary outcome. Incidence rates of HCC were determined per 1,000 person-years for all exposures. The study identified 207,367 adults with a prescription for a glucose-lowering agent. The risk of NAFLD was lower in patients prescribed a TZD than in those prescribed an SU (adjusted HR [aHR], 0.32; 95% CI, 0.20-0.51). No difference in risk of NAFLD was observed comparing GLP-1 receptor agonist use with insulin use (aHR, 1.22; 95% CI, 0.91-1.63). Conclusions Results of our study endorse the use of TZDs for selected patients at risk of NAFLD but do not support previous findings regarding the beneficial effect of GLP-1 receptor agonists. The low number of events in several subgroups may affect the generalizability of the current findings.
Hepatology, 74 (5)
ISSN:0270-9139
ISSN:1527-3350
Databáze: OpenAIRE
Externí odkaz: